DEC 24, 2015 10:32 AM PST

Immunotherapy Better for Non-Small-Cell Lung Cancer Patients

WRITTEN BY: Kara Marker
Some tumor cells in patients with non-small-cell lung cancer (NSCLC) express programmed death ligand 1 (PD-L1) that binds to its receptor (PD-1) which is expressed by immune cells. This interaction inhibits T cells’ ability to attack cancerous cells, allowing the tumor to grow unimpeded (Oncology). In attempt to block this inhibition, scientists are developing an immunotherapy that targets PD-1 and allows T cells to properly fight off growing cancer cells.

From the University of California, Los Angeles, researchers studied a group of patients with NSCLC to see how PD-1 immunotherapy compares with traditional chemotherapy.  Out of over a thousand participants, 75 percent had at least one percent of PD-L1 expressed by their tumor cells. The study results, which were published in The Lancet, showed groups of NSCLC patients receiving the PD-1 immunotherapy both experienced significant tumor shrinkage and lived longer than the patients who received chemotherapy.

"For most patients, this now offers data showing that immunotherapy leads to superior clinical outcomes with a side effect profile that is generally favorable to our traditional therapies," said Dr. Edward Garon, senior author of the paper.

Indeed, PD-1 immunotherapy utilizes the antibody pembrolizumab, which is significantly less toxic to cancer patients than chemicals used in chemotherapy.

NSCLC like squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are the most common types of lung cancer, making up 85 percent of all cases of lung cancer (American Cancer Society). Lung cancer is the leading cause of cancer death.

"This treatment provides real hope of long-lasting responses," Garon added.

For more about lung cancer, watch the following video.

Source: University of California, Los Angeles
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
NOV 11, 2019
Immunology
NOV 11, 2019
When the Cell Dials 9-1-1
Researchers can now explain how a cell that is being attacked by bacteria or viruses specifically manages to 'sound the alarm'...
NOV 11, 2019
Microbiology
NOV 11, 2019
Altering the Gut Microbiome Relieves Alzheimer's Symptoms in Mice
A link between the gut microbiome and Alzheimer's disease may help researchers treat the disease....
NOV 11, 2019
Health & Medicine
NOV 11, 2019
Blood-Brain Barrier Impairment and Its Role in Alzheimer's Disease
In healthy people, the blood-brain barrier (BBB), which is fromed by brain endothelial cells, strictly controls the entrance of harmful materials into...
NOV 11, 2019
Infographics
NOV 11, 2019
Surface Plasmon Resonance (SPR) Technology
Surface plasmon resonance (SPR) allows researchers to investigate different types of biomolecular interactions and mechanisms in real-time and label-free....
NOV 11, 2019
Health & Medicine
NOV 11, 2019
Study Links High Birth Weight to Risk of Allergies
Researchers from the University of Adelaide, Australia have linked the risk of developing childhood food allergies and eczema to heavier birth weight. The...
NOV 11, 2019
Immunology
NOV 11, 2019
Algorithm Predicts Response to HIV Immunotherapy
Blood samples from HIV patients produced the data necessary for two scientists to build a mathematical model for predicting how HIV patients will respond t...
Loading Comments...